Best Approach to Mild Pap Abnormalities?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

BETHESDA, Md--A new NCI study will evaluate three techniques to manage atypical squamous cells of undetermined significance that show up on Pap smears, including their cost effectiveness and acceptability to women.

BETHESDA, Md--A new NCI study will evaluate three techniques to manageatypical squamous cells of undetermined significance that show up on Papsmears, including their cost effectiveness and acceptability to women.

The trial will evaluate colposcopy; repeating Pap smears every six months;and human papillomavirus (HPV) testing as a means to differentiate betweenabnormalities that need immediate colposcopy and those that can best befollowed with repeat Pap tests at six-month intervals.

The study enrollment of 7,200 women with mild Pap test abnormalitiesshould be completed next year. Participants will be followed for threeyears. The study centers are the University of Alabama at Birmingham, Universityof Oklahoma, Magee-Womens Hospital, and the University of Washington.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.